STOCK TITAN

Amgen (NASDAQ: AMGN) EVP gets major equity grants and tax share withholding

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amgen EVP Murdo Gordon reported new equity awards and a small tax-related share withholding. On May 5, 2026, he received 3,640 Restricted Stock Units (RSUs) that vest in four equal annual installments of 25% starting on May 5, 2027, and will be settled in common shares. These RSUs include 458 Dividend Equivalents credited under Amgen’s Equity Incentive Plan. He was also granted 23,752 non-qualified stock options with a $329.59 exercise price, vesting 25% annually from May 5, 2027, and expiring on May 5, 2036. On May 6, 2026, 502 shares of common stock were disposed of at $329.59 per share to satisfy tax obligations, a non-market "F" code withholding. After these transactions, Gordon directly holds 51,837 Amgen common shares.

Positive

  • None.

Negative

  • None.
Insider Gordon Murdo
Role EVP, Global Commercial Ops
Type Security Shares Price Value
Tax Withholding Common Stock 502 $329.59 $165K
Grant/Award Nqso (Right to Buy) 23,752 $329.59 $7.83M
Grant/Award Common Stock 3,640 $0.00 --
Holdings After Transaction: Common Stock — 51,837 shares (Direct, null); Nqso (Right to Buy) — 23,752 shares (Direct, null)
Footnotes (1)
  1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 458 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
RSU grant 3,640 shares Restricted Stock Units granted May 5, 2026
Dividend Equivalents 458 units Credited to unvested RSUs under Equity Incentive Plan
Stock options granted 23,752 options Non-qualified stock options granted May 5, 2026
Option exercise price $329.59/share Conversion or exercise price for new options
Option expiration May 5, 2036 Non-qualified stock options expiry date
RSU vesting rate 25% annually Four annual installments starting May 5, 2027
Tax withholding shares 502 shares Shares disposed at $329.59 to satisfy tax liability
Post-transaction holdings 51,837 shares Common stock directly owned after reported transactions
Restricted Stock Units (RSUs) financial
"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Dividend Equivalents (DEs) financial
"These shares include 458 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan"
non-qualified stock options financial
"These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
Equity Incentive Plan financial
"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan)"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities"
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gordon Murdo

(Last)(First)(Middle)
ONE AMGEN CENTER DRIVE

(Street)
THOUSAND OAKS CALIFORNIA 91320

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Global Commercial Ops
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/05/2026A3,640(1)A$052,339D
Common Stock05/06/2026F502D$329.5951,837(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Nqso (Right to Buy)$329.5905/05/2026A23,75205/05/2027(3)05/05/2036Common Stock23,752$329.5923,752D
Explanation of Responses:
1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. These shares include 458 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
/s/ Murdo Gordon05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Amgen (AMGN) grant to EVP Murdo Gordon?

Amgen granted EVP Murdo Gordon 3,640 Restricted Stock Units and 23,752 non-qualified stock options. The RSUs vest 25% annually from May 5, 2027, and the options have a $329.59 exercise price and expire on May 5, 2036.

How do Murdo Gordon’s new Amgen (AMGN) RSUs vest over time?

Murdo Gordon’s 3,640 Restricted Stock Units vest in four equal annual installments of 25% each. Vesting begins on May 5, 2027, and each vested unit will be paid out in one share of Amgen common stock under the company’s equity plan.

What are the terms of Murdo Gordon’s new Amgen (AMGN) stock options?

Gordon received 23,752 non-qualified stock options with a $329.59 exercise price. These options vest and become exercisable in four equal 25% annual installments starting May 5, 2027, and they expire on May 5, 2036, if not exercised earlier.

Why did Murdo Gordon dispose of 502 Amgen (AMGN) shares?

The 502 Amgen shares were disposed of to cover tax liabilities related to equity awards. This Form 4 transaction is coded “F,” indicating payment of taxes by delivering securities, and does not represent an open-market sale initiated for investment reasons.

How many Amgen (AMGN) shares does Murdo Gordon hold after these transactions?

After the reported equity grant and tax withholding, Murdo Gordon directly holds 51,837 shares of Amgen common stock. This figure reflects his updated ownership following the RSU award, option grant, and the 502-share tax-withholding disposition.

What are Dividend Equivalents (DEs) in Murdo Gordon’s Amgen (AMGN) filing?

Dividend Equivalents are credits tied to unvested RSUs that mirror dividends on Amgen shares. Gordon’s holdings include 458 DEs, which will be paid in Amgen common stock on a one-to-one basis at vesting, plus cash for any remaining fractional share amount.